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Brain Aneurysms and Arteriovenous Malformations
Advancements and Emerging Treatments in Endovascular Embolization
Italo Linfante, MD; Ajay K. Wakhloo, MD, PhD
Background and Purpose—Brain aneurysms and vascular malformations can cause cerebral hemorrhages, with
devastating consequences for the patients and their families. Since the development of microcatheters and materials used
for endovascular embolization, we have witnessed a rapid advancement in the technology and in the number or patients
treated with this approach. The aim of this review is to survey recent data relevant to new technologies and emerging
treatment strategies in these areas.
Summary of Review—Clinical trials assessing the safety and efficacy of coil embolization for cerebral aneurysms were
based on the use of bare platinum, helical coils. Since then, endovascular operators have been testing and using new
materials such as bioactive coils, expandable coils, and complex-shaped coils. Based on the data so far obtained, third
and fourth generation coil designs are rapidly emerging and will be ready for clinical application in the near future.
Balloon- and stent-assisted coil embolization is enabling the treatment of complex, large-neck aneurysms and the
vascular reconstruction of lesions previously considered not treatable. New open- and closed-cell designs allow the
navigation and deployment of stents in extremely tortuous vessels. With regards to the embolization of vascular
malformations, it is possible to safely navigate microcatheters and microwires through very small arteries previously
considered not accessible. In addition, embolization materials such as n-butyl cyanoacrylate and ethylene-vinyl alcohol
copolymer are now routinely injected to safely reduce or obliterate large and complex arteriovenous malformations and
fistulae.
Conclusions—Advancements in technology are rapidly improving the endovascular approach to the treatment of cerebral
aneurysms and arteriovenous malformations. (Stroke. 2007;38:1411-1417.)
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According to angiographic and autopsy studies, intracra-nial aneurysms have a prevalence of between 0.5% and
6%. Most unruptured aneurysms remain undetected; how-
ever, increasing numbers of aneurysms are detected inciden-
tally during neuroimaging studies. A minority of aneurysms
are detected when they cause symptoms either by cranial
nerve compression or when they rupture, causing a subarach-
noid hemorrhage (SAH). Aneurysmal SAH (aSAH) can have
devastating consequences, with a reported case fatality of
32% to 67% and a 10% to 20% long-term dependence in
survivors.1–4
The first description of the endovascular approach to
embolize cerebral aneurysms was made by Fedor Serbinenko
in 1971.5 The Russian neurosurgeon described the use of
detachable balloons to occlude either the aneurysmal sac or
the parent vessel. In 1991 Guido Guglielmi introduced the use
of detachable coils for the treatment of intracranial aneu-
rysms.6–7 As described by the authors, platinum coils were
inserted into the aneurysmal sac and separated from a
stainless steel introducer by electrochemical detachment.
Initially, the treatment was reserved for aneurysms judged to
be at too high a risk for microsurgical clipping. However, as
technology and the operator’s ability improved, the use of
detachable coils rapidly spread. Ten years after its first
description, it was estimated that 1500 patients per month
were treated with endovascular embolization worldwide.8
To compare the safety and efficacy of endovascular em-
bolization versus microsurgical clipping, the International
Subarachnoid Aneurysm Trial (ISAT) investigators under-
took the first multicenter, randomized trial,9 which involved
42 centers in Europe and North America. The trial enrolled
2143 patients and randomly assigned them to neurosurgical
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clipping (n1070) or endovascular embolization with bare
platinum coils (n1073). The clinical outcomes were as-
sessed at 2 months and at 1 year, with interim ascertainment
of rebleeding and death. The primary outcome was a modi-
fied Rankin Scale score of 3 to 6 (dependency or death) at 1
year. Trial recruitment was stopped early by the steering
committee after a planned interim analysis revealed worst
outcomes in the neurosurgical group. In particular, 190 of 801
(23.7%) patients in the endovascular arm were dependent or
dead at 1 year compared with 243 of 793 (30.6%) treated with
microsurgical clipping (P0.0019).9 The relative and abso-
lute risk reductions in dependency or death after allocation to
an endovascular versus surgical treatment were 22.6% (95%
CI, 8.9 to 34.2) and 6.9% (2.5 to 11.3), respectively.9
The data from ISAT were the subject of debate in the
literature.10–11 Those in disagreement with the trial’s results
mainly argued that (1) the outcome of the surgical arm of
ISAT was worse than the previously published data, (2) the
location of the aneurysms randomized to both treatments was
biased for not being representative of the general population
of patients with aSAH, (3) the long-term outcome of the
endovascular treatment was unknown, and (4) the majority of
patients screened were not subject to randomization.
Although enrollment in ISAT was halted, the investigators
continued their long-term follow-up analysis on the patients
enrolled. The data published in 2005 showed that the early
survival advantage of the endovascular group was maintained
for up to 7 years and remained significant (log rank,
P0.03).12 The absolute reduction in the risk of death or
dependency increased to 7.4% in the endovascular arm. The
risk of epilepsy was substantially lower in patients treated
with coil embolization. However, the risk of rebleeding at
follow-up (7 years) was slightly higher in the endovascular
arm, 0.2% per patient-year as compared with surgical clip-
ping, 0.1% per patient-year (log rank, P0.22).12
The Cerebral Aneurysmal Rupture After Treatment
(CARAT) investigators compared rerupture rates after
aSAH.13 In an ambidirectional cohort study, 9 institutions
identified all ruptured saccular aneurysms treated between
1996 and 1998. A total of 1010 patients (711 surgically
clipped, 299 treated with coil embolization) were contacted
by written questionnaire or telephone. A neurologist, neuro-
surgeon, and neurointerventional radiologist independently
adjudicated possible reruptures. Rerupture of the treated
aneurysm after 1 year occurred in 1 patient treated with coil
embolization during 904 person-years of follow-up (annual
rate, 0.11%) and in no patients treated with surgical clipping
during 2666 person-years (P0.11). Aneurysm retreatment
after 1 year was more frequent in patients treated with coil
embolization; however, major complications were rare during
retreatment. The authors concluded that late events are
unlikely to overwhelm differences between the procedures at
1-year follow-up.13
Van Der Shaf et al recently reviewed randomized trials
comparing coiling versus microsurgical clipping in patients
with aSAH using the Cochrane Stroke Group Trials Register,
MEDLINE, and EMBASE.14 The analysis included 2272
patients (range per trial: 20 to 2143). At 1-year follow-up
evaluation, the relative risk of poor outcome for coiling
versus clipping was 0.76 (95% CI, 0.67 to 0.88). The absolute
risk reduction was 7% (95% CI, 4% to 11%). For patients
with SAH secondary to ruptured, anterior circulation aneu-
rysms, the relative risk of poor outcome was 0.78 (95% CI,
0.68 to 0.90) and the absolute risk decrease was 7% (95% CI,
3% to 10%). For posterior circulation aneurysms, the relative
risk was 0.41 (95% CI, 0.19 to 0.92) and the absolute
decrease in risk was 27% (95% CI, 6% to 48%).
Unruptured Intracranial Aneurysms
To treat or not to treat unruptured intracranial aneurysms
(UIA) is still a matter of debate.15–17 In 2000 the Stroke
Council of the American Heart Association published guide-
lines for the treatment of UIA.16 Currently, Raymond et al are
investigating these issues in a randomized trial.18 The discus-
sion of the variables that play a role in the decision on
whether to treat UIA is beyond the scope of this review. With
regards to the safety and efficacy of the endovascular treat-
ment for UIA, several authors indicate an overall 5% to 10%
risk of morbidity, mostly secondary to embolic phenomena,
and near 0% mortality.19–23 In the largest data set so far,
Johnston et al evaluated the safety of the endovascular
treatment compared with microsurgical clipping in 2069
patients treated in California hospitals for UIA from 1990 to
1998.24 In-hospital mortality and discharge to another health-
care facility rather than home were less frequent in the
endovascular group (10% versus 25%; P0.001). Mortality
was 0.5% in the endovascular group compared with 3.5% of
patients that underwent traditional clipping (P0.001).24 In a
meta-analysis of 48 studies over a 7-year period, Brilstra et al
reported a 6.7% rate of permanent complications for endo-
vascular treatment.19 The International Study of Unruptured
Intracranial Aneurysms (ISUIA) reported a 9.5% overall rate
of morbidity and mortality at 1 year after the endovascular
treatment of UIA.17 Aneurysmal rupture during coil emboli-
zation is one of the most feared complications of the
procedure. However, previously ruptured aneurysms are at a
much greater risk of intraprocedural rupture compared with
unruptured aneurysms. In particular, Tummala et al reported
a total of 10 intraprocedural ruptures in a series of 734
aneurysms.25 All ruptures occurred in previously ruptured
aneurysms.
Advancements in Technology
Recanalization of the aneurysmal sac is the main drawback of
endovascular embolization for both ruptured and UIA, occur-
ring in 4.7% to 38% of cases.26–28 The exact mechanism of
intra-aneurysmal thrombus formation and neo-intimal growth
across the neck after coil embolization is not completely
understood. It has been hypothesized that decreased blood
flow into the aneurysmal sac may initiate thrombosis, subse-
quent clot organization, and fibrosis.27–30 However, when
these processes do not take place, the force of pulsatile blood
flow against inert platinum may cause the coil mass to
compact or rearrange. Residual arterial blood flow in the
aneurysmal sac is thought to prevent thrombus organization,
leading to eventual aneurysmal recanalization and need for
retreatment.27–30
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Achieving a safe and permanent closure of the aneurysmal
sac has been the main focus of the research and development
of new materials for embolization.
The first described detachable coils (Guglielmi detachable
coils; Boston Scientific) were helical-shaped and made of
bare platinum. Platinum produces a delayed clot organization
and moderate inflammatory response.27,29 Several strategies
have been used to improve aneurysmal sac fibrosis and thus
avoid recanalization, such as: (1) increased packing density;
(2) the use of coils coated with a bioabsorbable polymeric or
expandable material such as hydrogel; (3) cytokines such as
growth factors and protein coatings; and (4) fibroblast tissue
allografts.31–39 In particular, bioabsorbable polymer was able
to stimulate an inflammatory reaction necessary to promote
early fibrosis of the aneurysmal sac in an animal model.
Matrix (90% polyglycolide- and 10% polylactide-coated
platinum coils; Boston Scientific) was the first coil commer-
cially developed for this purpose.31 Several single-center
series published so far on the use of matrix coils in both
ruptured and unruptured aneurysms suggested that the coil
has a good safety profile.39–41 With regards to efficacy, some
authors reported recanalization rates higher with matrix
compared with bare platinum coils.40,41 The high recanaliza-
tion rates were attributed to coil friction and compartmental-
ization attributable to the high amount of bioabsorbable
polymeric coating on the coil. In the new generation of matrix
coils, changes in the coil design were made to address these
issues. HydroCoil (Microvention/Terumo) is a platinum coil
coated with a material (hydrogel) that expands on contact
with blood.32,33 The HydroCoil for Endovascular Aneurysm
Occlusion (HEAL) study had enrolled 184 patients with 191
cerebral aneurysms as of February 2004.33 The preliminary
data showed that the initial occlusion and complication rates
were not significantly different from aneurysms treated with
bare platinum coils. Follow-up angiography is currently being
collected to determine whether HydroCoil can reduce the rate
of aneurysmal recanalization in their patient population.
Recently, Gaba et al reviewed the outcomes of 50 aneurysms
embolized primarily using HydroCoil and compared them
with aneurysms embolized with bare platinum coils.32 Em-
bolization with HydroCoil yielded a significantly greater
volumetric percentage sac occlusion (84.8% versus 29.8%;
P0.001). There were no differences in the length of hospital
stay. Follow-up angiography showed that recurrence rates
were significantly decreased in small aneurysms in the
HydroCoil cohort (5% versus 17%; P0.013).32 The data
have recently spurred debate.42
In an in vitro model, a higher packing density and better
aneurysmal filling and neck coverage were obtained with the
use of complex-shaped platinum coils (Orbit DCS; Cordis
Neurovascular, Inc) compared with helical coils.43 Recently,
a single-center prospective study reported on the use of these
types of coils to treat 77 aneurysms; follow-up was available
in 31 patients.44 The packing density was 3713.1%. No
rerupture was observed during the follow-up interval. Recan-
alization was observed in 4/31 aneurysms (12.9%). Excluding
basilar tip aneurysms from the analysis reduced the percent-
age of recanalization to 7%.
Balloon- and Stent-Assisted Embolization
The endovascular approach for the treatment of complex and
large-neck aneurysms is generally considered a challenge.
Nondetachable balloons and stents have been used by endo-
vascular operators as an aid to successfully perform coil
embolization.45,46 Moret et al described the technique of
temporarily inflating a balloon during coil positioning in
order to prevent coil herniation into the parent artery.45
Balloon-assisted coil embolization can also help to achieve a
more stable and higher packing density in these lesions.45,46
In their series, the authors reported 0.5% morbidity and 0%
mortality from the procedure. Angiographic follow-up
showed that complete occlusion occurred in 77% of aneu-
rysms, with 17% subtotal occlusion.45 Cottier et al reported
their experience in treating 49 aneurysms with balloon-
assisted coil embolization.46 In their series, 90% of aneu-
rysms that were completely occluded at initial treatment were
stable at follow-up evaluation; 15% that were subtotally
occluded were recanalized.
Stent-assisted coil embolization was also described as a
mean to safely embolize wide-neck or complex aneu-
rysms.47–49 Stent technology has markedly improved in the
last decade. A self-expanding, “open-cell” stent design allows
navigation and deployment in tortuous vessels.48,49 Self-
expanding, “closed-cell” stent designs are currently being
tested and will be available in the near future.50 At present,
reports from retrospective single-center case series suggest
that the stent-assisted coil embolization of large-neck and
complex aneurysms is feasible.47–49 With regards to delayed
in-stent stenosis, Fiorella et al reported data from a single-
center database of 156 patients in whom a stent was used for
treatment of large-neck aneurysms.49 In their series, 9 (5.8%)
developed moderate or severe delayed (2 months) in-stent
stenosis.49 Two of 9 were symptomatic and were treated with
angioplasty. Interestingly, the asymptomatic patients showed
partial or complete spontaneous resolution of the stenosis at
follow-up imaging.
Endovascular Treatment of
Arteriovenous Malformations
It has been reported that 2% of intracranial hemorrhages
are caused by a ruptured arteriovenous malformation
(AVM).50–52 Data from the New York Islands AVM Hemor-
rhage Study suggest that the AVM detection rate is 1.21/
100 000 person-years, and the incidence of AVM-hemor-
rhage is 0.42/100 000 person-years.53 Data from the
prospective, longitudinal, population-based Northern Man-
hattan Stroke Study suggest that the crude incidence for
first-ever AVM-related hemorrhage is 0.55/100 000 person-
years. In addition to hemorrhage, 15% to 35% of patients may
present with seizures as their first manifestation of a cerebral
AVM or ischemia secondary to “steal” phenomenon.54
With regards to outcomes from AVM-induced hemor-
rhages, Choi et al recently reported data on 241 consecutive
AVM patients from the prospective Columbia AVM Data-
bank.55 Among 241 AVM patients, 29 (12%) had subsequent
intracranial hemorrhage during follow-up. The authors then
compared 84 non-AVM patients with intracerebral hemor-
rhage from the Northern Manhattan Study (NOMAS) as
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control. Among AVM-hemorrhage subtypes, parenchyma-
tous AVM hemorrhage was associated with higher morbidity
(odds ratio, 2.9; 95% CI, 1.5 to 5.8 for National Institutes of
Health Stroke Scale 2) than nonparenchymatous hemor-
rhages. However, parenchymatous AVM hemorrhages fared
better in the long-term than non-AVM hemorrhages.55
The natural history of unruptured AVM is unclear. A
Randomized Trial of Unruptured Brain Arteriovenous mal-
formations (ARUBA) is underway to address this issue.56
Several predictive factors have been reported to be asso-
ciated with hemorrhage as presentation of an AVM.57–61
Recently, Stapf et al described their relevance for the risk of
subsequent hemorrhages in 622 consecutive patients from the
prospective Columbia AVM database.61 Increasing age (haz-
ard ratio, 1.05; 95% CI, 1.03 to 1.08), initial hemorrhagic
AVM presentation (hazard ratio, 5.38; 95% CI, 2.64 to
10.96), deep brain location (hazard ratio, 3.25; 95% CI, 1.30
to 8.16), and exclusive deep venous drainage (hazard ratio,
3.25; 95% CI, 1.01 to 5.67) were independent predictors of
subsequent hemorrhage. Annual hemorrhage rates on follow-up
ranged from 0.9% for patients without hemorrhagic AVM
presentation, deep AVM location, or deep venous drainage to as
high as 34.4% for those harboring all 3 risk factors.
Treatment
Treatment modalities for AVMs are surgery, radiotherapy,
and endovascular embolization. Such treatments can also be
combined and tailored to the particular features of the
AVM.62–67
Endovascular Embolization
Endovascular embolization is most commonly used to reduce
the size of the lesion in preparation for surgery or radiation
treatment.62–67 The first step entails placement of a micro-
catheter via AVM feeding arteries close to the “nidus”,
represented by a conglomeration of abnormal arteriovenous
connections at the precapillary level. At this point, an embolic
agent is infused in the nidus.62–67 Advancements in the
development of microcatheter technology and liquid embolic
agents have allowed the operator to be able to reach vessels
of extremely small caliber located in deep cerebral structures.
Traditionally, authors have reported variability in overall
complication rates (10% to 50% neurological deficit, 1% to
4% mortality). Recently, Haw et al reviewed their experience
on 306 patients who underwent 513 embolization sessions.68
The mortality rate was 2.6% and the morbidity was 4.9%. The
location of the AVM in an eloquent part of the brain, presence
of a larger fistula, and a venous deposition of liquid embolic
agent were related to complications. A clinically important
reduction in the rate of death and disabling morbidity oc-
curred in the second half of the study period. Similarly,
Ledezema et al performed a single-center, retrospective,
nonrandomized study of AVM embolization.69 Over an 11-
year period, 295 embolization procedures (761 pedicles
embolized) were performed in 168 patients with embolization
as the primary treatment modality (n16) or as an adjunct to
surgery (n124) or radiosurgery (n28). There were a total
of 27 complications, of which 11 were clinically significant.
Excellent or good outcomes (Glasgow Outcome Scale 4)
were observed in 152 (90.5%) patients. Unfavorable out-
comes (Glasgow Outcome Scale 1 to 3) were 3.0% at
discharge with a 1.2% embolization-related mortality. Predic-
tors of unfavorable outcome by univariate analysis were (1)
deep venous drainage (P0.05), (2) Spetzler-Martin Grade
III to V (P0.05), and (3) periprocedural hemorrhage
(P0.0001).
Most authors report complete AVM obliteration rates after
embolization alone of between 5% and 18%.70–73 Operator’s
experience and the improvement in microcatheters, micro-
wires, and embolization materials have made endovascular
embolization safer and more effective with regards to perma-
nent and complete obliteration of the AVM. Valavanis and
Yasargil reported rates of complete AVM obliteration of 39%
in 387 patients. In the subgroup analysis of 182 AVMs that
were treated with intent-to-cure they reported a cure rate of
75%.72 Similarly, Yu et al reported achieving complete
obliteration rates of 60% in patients treated with embolization
alone.73
The embolic agents currently used for the treatment of
AVMs include detachable coils, particles such as PVA
(polyvinyl alcohol), and liquid agents such as n-butyl cyano-
acrylate (n-BCA) and ethylene-vinyl alcohol copolymer.
Detachable coils have also been used in the obliteration of
AV fistulae and to decrease flow in AVMs in preparation for
liquid embolic agents.63–66,67 Some investigators have also
proposed the use of high-concentrated ethanol.74
Polyvinyl Alcohol
PVA particles are thrombogenic when infused into small
arteries. They are available in different diameters, as per the
selection of the operator based on the target vessels.75–78 The
embolization of AVM with particles alone presents several
issues.77–80 The process of nidus occlusion is slower with
PVA particles as compared with liquid embolic agents. In
addition, during embolization with particles, low-pressure
shunts are occluded first with an increase in pressure in the
still patent nidal vessels and feeders. The increased pressure
in the AVM feeders before they are completely obliterated
can increase the immediate risk of hemorrhage. Once AVMs
are embolized with PVA particles alone, recanalization rates
are usually high. Sorimachi et al reported a 43% rate of nidal
recanalization after embolization with PVA.79 Mathis et al
reported a 12% recanalization rate for AVMs embolized with
PVA in preparation for radiosurgery.80 Recanalization is
possibly secondary to the development of collaterals because
of proximal occlusion, particularly with larger-sized parti-
cles.75–78 For these reasons, AVM embolization with PVA is
currently performed mostly to reduce AVM flow in prepara-
tion for surgery.
n-Butyl Cyanoacrylate
n-BCA is an adhesive liquid monomeric agent that in contact
with a solution containing anions (ie, hydroxyl groups in
blood) quickly polymerizes and becomes solid.81 Such pro-
cess causes occlusion, marked inflammatory endothelial re-
sponse, and ultimately, fibrosis.82 The safety of n-BCA in
AVM embolization was tested in a prospective, randomized,
noninferiority trial on 114 patients.78 The authors showed that
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n-BCA was equivalent to PVA as a preoperative embolic
agent in achieving the prospective volume embolization goal
target (79.4% in the n-BCA group and 86.9% in the PVA
group) and in reducing the number of vessels embolized (2.2
in the n-BCA group and 2.1 in the PVA group). Because
n-BCA can achieve permanent obliteration, it has become the
most commonly used liquid embolic agent in the treatment of
AVM or AV fistulae of brain and spine.69,70,73,78,82–84 The
viscosity and timing of n-BCA polymerization are the main
limiting factors in achieving appropriate nidal occlusion.
Decreasing the amount of ethiodol in the mixture can reduce
viscosity. For deeper and more homogenous nidal penetration
a lower viscous mixture is recommended. To maintain a
delayed polymerization, changes in the pH of the solution are
recommended.83,84 The disadvantages of n-BCA are the
following: (1) proper delivery of the agent into the nidus
requires accurate polymerization time; (2) prolonged injec-
tions are difficult; therefore, only a limited amount of nidal
vessels can usually be occluded with a single injection; and
(3) because n-BCA is adhesive, catheter retention is a
possible risk.78,82–84
Ethylene-vinyl Alcohol Copolymer
Ethylene-vinyl alcohol copolymer (EVOH) and dimethyl
sulfoxide (DMSO) is a nonadhesive solution developed for
the treatment of AVM and arteriovenous fistula.85,86 In Onyx
(EV3), EVOH is formed of 48 mol/L ethylene and 52 mol/L
vinyl alcohol.87 The polymer is dissolved in DMSO and is
prepared in different concentrations. Micronized tantalum
powder (35% weight/volume) is added for radiopacity. The
lower the concentration of the copolymer, the less viscous the
agent, the more distal is the penetration of the mixture. Jahan
et al in a phase I study reported their experience embolizing
129 feeding arteries in 33 procedures on 23 patients.87 The
authors showed an average 63% reduction in AVM volume
with the use of Onyx. Two patients experienced ischemia
because of the inadvertent occlusion of a feeder. One made a
full recovery, and the other had a permanent deficit. Because
of its nonadhesive nature, Onyx offers some advantages: (1)
long and controlled infusion of the agent can be performed,
consequently a large section of the nidus can be potentially
embolized with a single feeder injection; and (2) cerebral
angiography can be obtained in-between Onyx infusion. The
operator can therefore monitor the degree of nidal occlusion
and assess the state of the draining veins.87 The disadvantages
of Onyx include the following: (1) DMSO can be potentially
angiotoxic, in particular with rapid injection86–88; (2) DMSO
volume and injection time need to be monitored closely to
achieve a safe embolization of AVMs; (3) only catheters that
are DMSO-compatible can be used with Onyx; and (4)
visibility can be limited in smaller feeding pedicles attribut-
able to the separation of Onyx and the added opacifying agent
Tantalum.86,87 Although Onyx is nonadhesive, only partial
reflux can be allowed around the catheter tip because it may
still make catheter withdrawal difficult.87
Controlled randomized studies are currently underway to
compare safety and efficacy of the different liquid embolic
materials.
Conclusions
The permanent and safe obliteration of cerebral aneurysms
and AVMs is the main goal of any treatment. Endovascular
embolization offers a new, minimally invasive approach to
these lesions. The technology available to the endovascular
operators is rapidly improving, as outlined by this review.
The clinical trials that are either underway or in the design
stage will be challenged by the fast advancement of the
technology and materials available to the operators. Never-
theless, clinical trials are needed as endovascular manage-
ment continues to develop and advance as a powerful
treatment option for cerebral aneurysms and AVMs.
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